%0 Journal Article
%A Tong, Hoi Yan
%A Borobia, Alberto
%A Quintana Díaz, Manuel
%A Fabra, Sara
%A González Viñolis, Manuel
%A Fernández Capitán, Carmen
%A Rodriguez Dávila, María
%A Lorenzo, Alicia
%A López Parra, Ana María
%A Ruiz Giménez, Nuria
%A Abad Santos, Francisco
%A Suarez, Carmen
%A Madridano, Olga
%A Gómez Cerezo, Jorge
%A Llamas, Pilar
%A Baeza Richer, Carlos Ignacio
%A Arroyo Pardo, Eduardo
%A Carcas, Antonio J.
%T Acenocoumarol Pharmacogenetic Dosing Algorithm versus Usual Care in Patients with Venous Thromboembolism: A Randomised Clinical Trial
%D 2021
%@ 2077-0383
%U https://hdl.handle.net/20.500.14352/7415
%X Patients with venous thromboembolism (VTE) require immediate treatment with anticoagulants such as acenocoumarol. This multicentre randomised clinical trial evaluated the effectiveness of a dosing pharmacogenetic algorithm versus a standard-of-care dose adjustment at the beginning of acenocoumarol treatment. We included 144 patients with VTE. On the day of recruitment, a blood sample was obtained for genotyping (CYP2C9*2, CYP2C9*3, VKORC1, CYP4F2, APOE). Dose adjustment was performed on day 3 or 4 after the start of treatment according to the assigned group and the follow-up was at 12 weeks. The principal variable was the percentage of patients with an international normalised ratio (INR) within the therapeutic range on day 7. Thirty-four (47.2%) patients had an INR within the therapeutic range at day 7 after the start of treatment in the genotype-guided group compared with 14 (21.9%) in the control group (p = 0.0023). There were no significant differences in the time to achieve a stable INR, the number of INRs within the range in the first 6 weeks and at the end of study. Our results suggest the use of a pharmacogenetic algorithm for patients with VTE could be useful in achieving target INR control in the first days of treatment.
%X Hoi Yan Tong
%~